Physician profile
Christopher E Chandler
NPI 1972992329
$4,051.93
in general payments reported to CMS, 2019-2025
23 companies · $836 in 2025
The $836 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,121 · 2022: $852 · 2023: $638 · 2024: $605 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.81 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.53 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $481.15 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $435.80 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $340.02 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $331.66 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $325.19 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $320.95 | 2021-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $319.52 | 2021-2025 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $116.12 | 2024 | |
| Sunovion Pharmaceuticals INC. | $114.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.71 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $90.62 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $86.55 | 2024-2025 | Cobenfy |
| Corium, LLC | $84.87 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $82.09 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $74.72 | 2023-2024 | Jornay Pm |
| Janssen Scientific Affairs, LLC | $69.77 | 2024-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $42.09 | 2023-2025 | |
| Indivior INC. | $17.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.77 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.33 | 2025 | Jornay Pm |
| Eisai INC. | $15.10 | 2021 | |
| Adlon Therapeutics L.P. | $14.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.